Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.